Foundayo: all about this new GLP-1 pill for weight loss

Hoping to lose weight with a GLP-1 medication, but turned off by giving yourself a shot, and the timing requirements of the Wegovy pill? Good news: Foundayo (orforglipron) is the first oral GLP-1 for weight loss that can be taken at any time of day, with or without food — and it’s officially available in the United States. 

Here's what you need to know about the Foundayo weight loss pill, how it works, how it compares to oral Wegovy, and more. 

Foundayo is an oral GLP-1 medication that was approved by the US Food and Drug Administration (FDA) for weight loss and management on April 1, 2026. It’s developed by Eli Lilly, the same manufacturer behind weight loss injection Zepbound. 

Here's the need-to-know:

• Foundayo is a once-daily pill without any fasting requirements. That’s a key difference from oral semaglutide (Wegovy pill, Rybelsus), which must be taken on an empty stomach with a little water, at least 30 minutes before any other pills, food, or drinks. 

• It contains orforglipron as its active ingredient. Foundayo is the brand-name version of orforglipron, a non-peptide (this is key!) GLP-1 receptor agonist. Its more stable molecular structure allows it to be better absorbed in the gut, unlike most GLP-1s, which are peptides.

• As of April 6, 2026, Foundayo is available in the US in six dosage strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg.  

• Foundayo led to a weight loss of up to 11.2% in adults without diabetes after 72 weeks in clinical trials. This is slightly less than the Wegovy pill, which produced 13.6% weight loss after 64 weeks.

Check your coverage for FDA-approved GLP-1s—for free

Check for free

The Foundayo weight loss pill is a GLP-1 medication — the same drug class as semaglutide. Meaning, it generally works the same way, by mimicking glucagon-like peptide-1 (GLP-1), a natural gut hormone that helps regulate blood sugar levels, digestion, and appetite. 

More specifically, Foundayo targets GLP-1 receptors and, in turn:

• Slows stomach emptying, helping you feel full faster and stay full for longer

• Decreases appetite and "food noise," helping you consume fewer calories per day

• Increases insulin release, helping keep blood sugar levels in check

Foundayo can cause up to 11.2% weight loss after 72 weeks (about a year and 4–5 months), according to clinical trials. If your starting weight is 250 pounds, that's a loss of 28 pounds. 

Here's the clinical study data:

• In a clinical trial involving 272 adults with overweight or obesity, 36 weeks of daily orforglipron treatment resulted in an average weight loss of 9.4%–14.7%. In contrast, the placebo group lost an average of 2.3%.

• In the ATTAIN-1 trial, which included 3,127 adults with overweight or obesity, orforglipron users lost an average of 7.5%–11.2% body weight over 72 weeks. The placebo group experienced about 2% weight loss.

• The ATTAIN-2 trial, of 1,613 adults with obesity and type 2 diabetes, found that orforglipron users lost an average of 5.1%–9.6% body weight over 72 weeks. The placebo group lost about 2.5%. 

An important point: Clinical trials involved Foundayo doses of up to 36 mg (capsule formulation) per day. Lilly has previously said that this dose is bioeqivalent to the FDA-approved maximum of 17.2 mg per day, according to GenEdge. So, the approved dosing schedule is considered to match the dosing schedule studied in clinical trials, even though the milligram number may not be the same. 

The Foundayo pill is taken once a day. It can be taken at any time of day, with or without food, and is available in six dosage strengths:

• 0.8 mg 

• 2.5 mg

• 5.5 mg

• 9 mg

• 14.5 mg

• 17.2 mg

Like oral Wegovy dosing, Foundayo follows a gradual step-up schedule, slowly increasing the dosage to give your body time to adjust. Individual dose escalation is determined by the prescriber. Not everyone can tolerate (or needs) the maximum dose.

Here's the general dosing schedule:

Common Foundayo side effects are similar to those of other GLP-1s. These include:

• Nausea

• Constipation

• Diarrhea

• Abdominal pain

• Headache

• Vomiting

• Heartburn

• Fatigue

• Burping (eructation)

• Flatulence (gas)

• Reflux

• Hair loss

Like other GLP-1 medications, Foundayo can cause serious side effects such as pancreatitis, kidney damage, or hypoglycemia (low blood sugar).

Give your healthcare provider a full list of your other medications before starting Foundayo. This pill can interact with several other drugs, including medications that affect liver enzymes, simvastatin (a cholesterol medication), and diabetes medications. 

Foundayo is not recommended for people with liver impairment or a personal or family history of thyroid tumors or multiple endocrine neoplasia type 2 (MEN2). 

Foundayo should not be taken by anyone while pregnant. There’s not enough data to determine whether Foundayo is safe while breastfeeding.

Foundayo is currently available for weight loss on Ro and through LillyDirect, the manufacturer’s direct-to-patient program.  

Without insurance, Foundayo starts at $149 per month. Exactly how much you’ll pay depends on the dose (if prescribed). 

Here’s a breakdown of the cash-pay prices for Foundayo on Ro:

• $149 per month: 0.8 mg dose 

• $199 per month: 2.5 mg dose

• $299 per month: 5.5 mg and 9 mg doses 

• $299 per month: 14.5 mg and 17.2 mg doses (with manufacturer offer)

With insurance, Foundayo can cost as little as $25 per month with the manufacturer savings card, according to Lilly. Eligible Medicare Part D enrollees may be able to get Foundayo for $50 per month starting in July 2026.

See if you qualify

Wondering how the Foundayo weight loss pill compares to the Wegovy pill? Well, there are a few key differences between the two oral GLP-1s for weight loss:

• Active ingredient. Foundayo contains orforglipron, and Wegovy contains semaglutide. Both active ingredients are classified as GLP-1 medications.

• Approved uses. Foundayo is approved for weight loss and weight management in adults with obesity and overweight. Wegovy is approved for weight loss, weight management, and reducing cardiovascular risks in certain populations.

• Fasting protocol. Where Wegovy must be taken on an empty stomach and followed by a 30-minute fast, Foundayo is a non-peptide, allowing it to be taken with or without food.

• Weight loss effectiveness. Post-trial data are still emerging, but we can say that orforglipron resulted in up to 11.2% weight loss after 72 weeks at the highest studied dose, whereas oral semaglutide caused an average 13.6% weight loss after 64 weeks at the highest approved dose (25 mg daily).

Foundayo is a brand-new oral GLP-1 medication from manufacturer Eli Lilly that could help you lose weight. Here's a recap on the Foundayo weight loss pill:

• Foundayo is a daily oral GLP-1 medication made by Eli Lilly that was approved by the FDA for weight loss and management in early April 2026. It is available in the US in six dosage strengths, ranging from 0.8 mg to 17.2 mg. 

• Upon being approved, it became the only GLP-1 pill on the market that can be taken any time of day, with or without food. Thanks to a different molecular structure than other oral GLP-1s (i.e. it’s not a peptide), Foundayo is more easily absorbed in the gut — and thus can be taken at mealtimes (or not!).

• It can be effective for weight loss. In clinical trials, the Foundayo pill led to 11.2% weight loss after 72 weeks at the maximum studied dose. 

• Foundayo is available on Ro. If prescribed, you can get Foundayo for the cash price of $149–$299 per month, depending on dose.